• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

    9/25/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    --Combined Funding Strengthens Bay Area Community with STEM Curriculum, Building Scientific, Technology and Mathematics Literacy--

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company's ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and work, including a $1 million grant to the Boys and Girls Clubs of America and $500,000 to the San Mateo Foster City Education Foundation to build STEM curriculum.

    With STEM skills projected to be essential for 80% of all jobs by the end of the decade, the Gilead Foundation's investment is a powerful step toward closing the opportunity gap and preparing students for the future. The U.S. faces a projected shortfall of 1.4 million skilled STEM workers by 2030, making access to STEM education more urgent than ever.

    "The Gilead Foundation's commitments will help promote promising futures for students in the Bay Area and beyond with the goal of strengthening our local communities," said Keeley Wettan, Senior Vice President, Legal at Gilead and Gilead Foundation Board Member. "STEM skills have become a necessity for the modern workforce across the country, but many students need better access to the educational experiences needed to grow these skills. We're proud to partner with organizations that are on the front line of this work."

    The Gilead Foundation's grants will support organizations working to strengthen STEM learning opportunities for students from elementary school through college. Recent commitments include:

    • A $1 million grant to the Boys and Girls Clubs of America to support STEM programs for elementary through high school students in eight sites across the Bay Area, Los Angeles, Maryland, Washington D.C., New Jersey and North Carolina.
    • A $500,000 grant to the San Mateo Foster City Education Foundation to support STEM education for elementary and middle school students in the San Mateo-Foster City School District.
    • $5 million in grants to San Francisco State University to support the construction of their new Science and Engineering Innovation Center (SEIC) and student programming.

    "High-quality STEM education is critical for building a skilled workforce, but too many students lack access to these opportunities," said Lisa Anastasi, Executive Vice President and Chief Development and External Relations Officer at Boys & Girls Clubs of America. "We must work to close the skills gap and empower every young person to explore the possibilities of STEM, including potential career paths. We're proud to partner with the Gilead Foundation to help build a STEM workforce that reflects the talent and potential in all our communities."

    "Every student deserves access to STEM experiences, regardless of their background or zip code," said Diego Ochoa, Superintendent of the San Mateo-Foster City School District. "STEM education not only builds scientific, technological and mathematical literacy, but also cultivates seminal problem-solving skills and critical thinking in our students. When these opportunities aren't accessible to all, we lose out on incredible potential. It's time to change the narrative and the reality: all kids deserve the opportunity to be in STEM."

    These recent investments follow the official launch of San Francisco State University's SEIC facility, which opened its doors earlier this year, serving a predominantly local student population drawn from Bay Area communities. The Gilead Foundation's grant provided state of the art research equipment and resources to support students' pursuit of STEM degrees - and careers - across biopharma, biotech and engineering.

    "We're so grateful for the Gilead Foundation's generous investment in San Francisco State University," said Carmen Domingo, Dean of the College of Science and Engineering at SFSU. "Our students will be the next generation of scientists, engineers and healthcare professionals pushing us forward, and it's crucial that they are given the opportunity to be trained on modern technologies and with tools that are most in demand. The resources housed in the new Science and Engineering Innovation Center will greatly increase our ability to prepare students to thrive across careers in STEM in our communities."

    The Gilead Foundation's investments build on the company's longstanding commitment toward supporting organizations in the Bay Area, including those building the next-generation STEM workforce. Since 2018, Gilead has awarded more than $150 million in grant funding to nearly 250 nonprofit organizations in the region working to advance education equity and strengthen a diverse workforce pipeline.

    About the Gilead Foundation

    The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

    # # #

    Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

    For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250925022835/en/

    Jessica Smith, Media

    [email protected]

    Jacquie Ross, Investors

    [email protected]

    Get the next $GILD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    8/8/2025$127.00Hold → Buy
    Truist
    7/25/2025$133.00Hold → Buy
    Needham
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $GILD
    SEC Filings

    View All

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    9/15/25 4:04:03 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form N-PX filed by Gilead Sciences Inc.

    N-PX - GILEAD SCIENCES, INC. (0000882095) (Filer)

    8/29/25 10:09:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    8/14/25 4:08:22 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, Controllership Burkhart Erin

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/23/25 7:55:57 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Burkhart Erin

    3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/23/25 7:53:59 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Mercier Johanna sold $340,710 worth of shares (3,000 units at $113.57), decreasing direct ownership by 3% to 113,193 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/16/25 5:16:01 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

    --Combined Funding Strengthens Bay Area Community with STEM Curriculum, Building Scientific, Technology and Mathematics Literacy-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company's ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and

    9/25/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

    Company's Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma's recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the potential global impact of the company's in vivo engineered cell therapy platform in immuno-oncology and

    9/22/25 7:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gilead Sciences upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Gilead Sciences from Neutral to Outperform and set a new price target of $128.00

    8/19/25 8:30:09 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by Truist with a new price target

    Truist upgraded Gilead Sciences from Hold to Buy and set a new price target of $127.00

    8/8/25 7:56:58 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by Needham with a new price target

    Needham upgraded Gilead Sciences from Hold to Buy and set a new price target of $133.00

    7/25/25 8:51:37 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Financials

    Live finance-specific insights

    View All

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

    – Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection – – Accelerated EC Decision Comes After U.S. FDA Approval in June – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the European Union's 27 member states, as we

    8/26/25 3:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces Second Quarter 2025 Financial Results

    Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world's first twice-yearly HIV prevention option," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward

    8/7/25 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

    12/12/24 5:30:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

    Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

    6/15/23 4:01:00 PM ET
    $GILD
    $GLPG
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Electromedical & Electrotherapeutic Apparatus